Cat. #151890
T47D-182R2 Cell Line
Cat. #: 151890
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Organism: Human
Tissue: Breast
Disease: Cancer
Model: Tumour line
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Anne Lykkesfeldt
Institute: Danish Cancer Society
Tool Details
*FOR RESEARCH USE ONLY
- Name: T47D-182R2 Cell Line
- Tool sub type: Continuous
- Parental cell: T47D
- Organism: Human
- Tissue: Breast
- Disease: Cancer
- Model: Tumour line
- Description: The T47D-182R2 Cell Line is a breast cancer cell line resistant to fulvestrant. Treatment with the steroidal antiestrogen fulvestrant has proven effective upon progression on tamoxifen therapy and is now approved for second-line treatment after tamoxifen or aromatase inhibitors. As for tamoxifen treatment of advanced breast cancer, resistance will inevitably occur also for fulvestrant. Clarification of the molecular changes associated with the resistant growth is needed to find targeted treatments to resistant tumour cells and treatments that can inhibit or delay the emergence of resistance.
- Production details: Human breast cancer cell line derived from T47D/S5 by long term treatment with 100 nM fulvestrant. Grow with 5% feal calf serum and 100 nM fulvestrant. Estrogen and progesterone receptor negative. Passage 165 (AL3370, AL3384)
- Cellosaurus id: CVCL_1D35
Target Details
- Target: Oestrogen receptor
Applications
- Application notes: Estrogen and progesterone receptor negative.
Handling
- Format: Frozen
- Passage number: Passage 165 (AL3370, AL3384)
- Growth medium: Phenol red free RPMI 1640 + 5% FCS + glutamax + 8??g Insulin/ml + 100 nM fulvestrant. Grow with 5% feal calf serum and 100 nM fulvestrant.
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
Related Tools
- Related tools: T47D/S2 Cell Line
References
- Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.
- Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.
- Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
- SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
- Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.
- T47D breast cancer cells switch from ER...
